Identification of novel cell-wall active antifungal compounds.

Fungal infections of humans and other animals are serious and often life threatening, especially in immunocompromised patients. One difficulty in treating fungal disease is the limited arsenal of antifungal compounds. The recent regulatory approval of three cell-wall active antifungal compounds encourages the search for additional clinical candidates that inhibit fungal cell wall formation.

Novel compounds active against Leishmania major.

Leishmania major is an important trypanosomatid pathogen that causes leishmaniasis, which is a serious disease in much of the Old World. Current treatments include a small number of antimony compounds that, while somewhat effective, are limited by serious side effects. We have screened a small portion of a unique chemical library and have found at least three novel compounds that are effective against L.